New data presented at ESMO 2020 have shown that immunotherapy is beneficial for patients with gastric and oesophageal cancers who currently have poor survival. Immune therapy would be a big change in...

(HealthDay)—Increasing adherence to evidence-based prophylaxis protocols for epidermal growth factor receptor inhibitor (EGFRi)-associated rash can reduce interventions and toxicity-associated chemotherapy...